Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 May 3;51(5):1702617.
doi: 10.1183/13993003.02617-2017. Print 2018 May.

Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation

Affiliations
Free article
Observational Study

Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation

Anne Bergeron et al. Eur Respir J. .
Free article

Abstract

Epidemiological data on late-onset noninfectious pulmonary complications (LONIPCs) following allogeneic haematopoietic stem cell transplantation (HSCT) are derived exclusively from retrospective studies and are conflicting. We aimed to evaluate prospectively the incidence, risk factors and outcomes for LONIPCs.All consecutive patients scheduled to receive allogeneic HSCT between 2006 and 2008 at a university teaching hospital in France were screened for inclusion in the study. Eligible patients were those surviving at day 100. Among 243 screened patients, 198 patients were included in the analysis. The median (interquartile range) follow-up was 72.3 (15.2-88.5) months. 55 LONIPCs were diagnosed in 43 patients. Bronchiolitis obliterans syndrome (n=22) and interstitial lung disease (n=12) were the most common LONIPCs. At 36 months after inclusion, the estimated cumulative incidence of LONIPCs was 19.8% (95% CI 14.2-25.3%). The estimated median survival after the diagnosis of LONIPCs was 78.5 months (95% CI 20.0-not reached). Based on a multivariate Cox model, a history of chest irradiation anytime prior to HSCT, a history of pneumonia within 100 days post-HSCT and a low mean forced expiratory flow at 25-75% of forced vital capacity at day 100 were associated with the development of LONIPCs.Our data provide clues to identify patients at high risk of developing LONIPCs. These patients should be targeted for close monitoring to provide earlier LONIPC treatment or prophylactic treatment.

Trial registration: ClinicalTrials.gov NCT01219972.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A. Bergeron has received personal fees for lectures from Gilead and Pfizer, and personal fees for lectures and board participation from Merck, outside the submitted work. R. Peffault de Latour has received personal fees and grants from Alexion, Novartis and Pfizer, and research grants from Amgen, outside the submitted work. K. Chagnon has received personal fees from AstraZeneca, outside the submitted work.

Publication types

MeSH terms

Associated data